sustanon cycle

The date of first use of the cartridge should be noted on the sticker that comes with the cartridge, and stick it on a box with a syringe-pen. Detailed instructions on the use of sustanon cycle enclosed in the package.

Overdose
reports of overdose there is, however, re-introduction of large doses of interferon can be accompanied by profound lethargy, sluggishness, prostration and coma. Such patients should be hospitalized for observation and appropriate supportive measures.

Side effects:
The following data on the side effects of the drug are based on the experience of the treatment of patients with various malignant diseases, is often refractory to previous therapy and are at the later stages, as well as patients with chronic hepatitis B and chronic hepatitis C.

Clinical researches

O6schie symptoms. Often – flu-like symptoms (fatigue, fever, chills, loss of appetite, muscle and headaches, joint pain, and sweating), weight loss. These acute side effects usually get better or eliminated, while the appointment of paracetamol, and their severity during the treatment or change the dose of the drug sustanon cycle tends to decrease, although continuing therapy can cause drowsiness, weakness and lethargy.

Gastrointestinal tract. Often – about two-thirds of cancer patients – anorexia, half – nausea. Quite often – vomiting, change in taste, dry mouth, diarrhea and mild or moderate abdominal pain. Rarely – constipation, flatulence, increased peristalsis and heartburn, aggravation of peptic ulcer disease, gastrointestinal bleeding, are not life-threatening pancreatitis.

Changes in liver function. Sometimes – raising the level, alkaline phosphatase,  and bilirubin, which, as a rule, do not require dose adjustment. Rarely – changing activity of transaminases in hepatitis B usually indicates an improvement in the clinical condition of the patient.

Central nervous system. Sometimes – systemic and non-systemic dizziness, worsening mental status, forgetfulness, depression, drowsiness, confusion, behavioral disorders (anxiety, nervousness) and sleep disorders. Rare – severe drowsiness, convulsions, coma, cerebrovascular accidents, temporary impotence, as well as suicidal thoughts, suicide attempts and suicide (suicidal behavior).

The body of. Sometimes it – blurred vision. Rarely – ischemic retinopathy. Very rare – retinopathy including retinal hemorrhages, and cotton wool exudates, papilledema, thrombosis of the central retinal artery and vein, posterior ischemic neuropathy.

The peripheral nervous system. Sometimes – paresthesia, numbness, neuropathy, itching and tremor.

. Cardiovascular and respiratory systems Quite sustanon cycle often – about one fifth of cancer patients – Arterial transient hypo- and hypertension, edema, cyanosis, arrhythmias, palpitations and chest pain. Rarely – slight cough and shortness of breath, pulmonary edema, pneumonia, congestive heart failure, cardiac arrest and respiratory arrest, myocardial infarction. In patients with hepatitis B, cardiovascular disorders are very rare.

The skin, its appendages and mucous membranes. Quite often – a fifth of the patients – mild to moderate hair loss, reversible following cessation of treatment. Increased hair loss may continue for several weeks. Rarely – exacerbation of herpes sores on the lips, rash, itching, dry skin and mucous membranes, nasal discharge, and nasal bleeding.

The kidneys and urinary tract. Rarely – the deterioration of renal function, acute renal failure (primarily in cancer patients with risk factors such as the kidney and / or concomitant treatment with nephrotoxic drugs the disease), electrolyte disorders, especially anorexia or dehydration, proteinuria, increase of cell elements in the urine sediment, increase of urea, creatinine and uric acid, and serum.

. Hematopoiesis system Quite often – transient leukopenia (rarely require dose reduction) in patients in a state of myelosuppression – thrombocytopenia, decreased hemoglobin levels. Sometimes – thrombocytopenia in patients without myelosuppression. Rarely – reduction of hemoglobin and hematocrit. Return of severe haematological disorders to baseline is usually seen 7-10 days after discontinuation of treatment . Very rarely, idiopathic thrombocytopenic purpura.

Other. Rarely – hyperglycemia, diabetes mellitus, injection site reactions, including very rarely – necrosis, autoimmune pathology (vasculitis, arthritis, hemolytic anemia, thyroid dysfunction, lupus-like syndrome). Very rarely – sustanon cyclehypocalcaemia, sarcoidosis, gipertriglitseridmiya / hyperlipidemia.

Buy steroids in our shop